Gene therapy for cystic fibrosis: which postman, which box?
- PMID: 9659356
- PMCID: PMC1745161
- DOI: 10.1136/thx.53.3.197
Gene therapy for cystic fibrosis: which postman, which box?
Abstract
Since 1989 when the gene responsible for cystic fibrosis was cloned and designated the cystic fibrosis transmembrane conductance regulator (CFTR) gene, considerable progress has been made in the development of gene therapy for this disease. Clinical trials have already been performed using cationic liposome and adenoviral based gene transfer systems, measuring the safety and efficacy of this new form of treatment, with variable results to date. These two approaches and the current progress in airway gene delivery are discussed.
Comment in
-
Gene therapy for cystic fibrosis: what message for the recipient?Thorax. 1998 Mar;53(3):157-8. doi: 10.1136/thx.53.3.157. Thorax. 1998. PMID: 9659347 Free PMC article. No abstract available.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical